Northern Trust Corp Aim Immuno Tech Inc. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

A detailed history of Northern Trust Corp transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Northern Trust Corp holds 85,119 shares of AIM stock, worth $19,577. This represents 0.0% of its overall portfolio holdings.

Number of Shares

85,119

Previous 85,119 -0.0%

Holding current value

$19,577

Previous $31,000 29.03%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.35 - $0.61 $30 - $53	-87 Reduced 0.1%	85,119 $31,000
Q1 2024 May 14, 2024	SELL	$0.33 - $0.48 $118 - $172	-360 Reduced 0.42%	85,206 $40,000
Q3 2023 Nov 13, 2023	SELL	$0.44 - $0.71 $418 - $675	-951 Reduced 1.1%	85,566 $39,000
Q3 2022 Nov 14, 2022	SELL	$0.57 - $0.81 $1,248 - $1,773	-2,190 Reduced 2.47%	86,517 $50,000
Q1 2022 May 13, 2022	BUY	$0.67 - $1.18 $30 - $53	45 Added 0.05%	88,707 $94,000
Q4 2021 Feb 08, 2022	BUY	$0.92 - $1.96 $226 - $482	246 Added 0.28%	88,662 $82,000
Q3 2021 Nov 15, 2021	BUY	$1.91 - $2.17 $2,272 - $2,582	1,190 Added 1.36%	88,416 $179,000
Q2 2021 Aug 13, 2021	BUY	$1.93 - $2.39 $37,596 - $46,557	19,480 Added 28.75%	87,226 $188,000
Q1 2021 May 12, 2021	BUY	$1.88 - $2.82 $6,472 - $9,709	3,443 Added 5.35%	67,746 $154,000
Q4 2020 Feb 11, 2021	SELL	$1.68 - $2.45 $1,619 - $2,361	-964 Reduced 1.48%	64,303 $115,000
Q3 2020 Nov 16, 2020	BUY	$1.77 - $3.88 $13,630 - $29,879	7,701 Added 13.38%	65,267 $140,000
Q2 2020 Aug 14, 2020	BUY	$1.9 - $2.94 $109,375 - $169,244	57,566 New	57,566 $143,000

Others Institutions Holding AIM

# of Institutions

Shares Held

9.01M

Call Options Held

Put Options Held

View Full List

About AIM ImmunoTech Inc.

Ticker AIM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,049,300
Market Cap $11.1M
Description
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...

More about AIM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Aim Immuno Tech Inc. Transaction History